Trial NCT03802630

View at ClinicalTrials.gov 
Org. Study IDs: CRTH258C2301
Secondary IDs: 2018-001842-33

Last trial update was posted on 2023-01-30

MeSH Interventions

Aflibercept

MeSH Conditions

Macular Edema Retinal Vein Occlusion Vision Disorders Vision, Low

Other Conditions

Branch Retinal Vein Occlusion

Stopping Reasons

Study was terminated by sponsor due to increased incidences of AEs of special interest (intraocular inflammation including retinal vasculitis and retinal vascular occlusion), in patients dosed brolucizumab 6mg every 4 weeks beyond 3 initial doses

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID